Anil Dhawan MBBS MD FRCPCH,
bit.bio SAB member, added: “With its unique precision cell programming technolog y,
bit.bio has the solution to the key problem for cell based therapies – namely access to an affordable, scalable and consistent supply of human cells. I am so excited that
bit.bio’s lead programme builds on our previous work in liver disease, and I am looking forward to working with the
bit.bio team to develop a life-saving treatment to the thousands of ALF and ACLF patients that so desperately need it.”